Asthma Clinical Research Studies

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Summa Health System

mi

from

Akron, OH

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

University of Cincinnati Medical Center

mi

from

Cincinnati, OH

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Metro Health Medical Center

mi

from

Cleveland, OH

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Lehigh Valley Hospital Mental Health Clinic

mi

from

Allentown, PA

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Albery Einstein Medical Center

mi

from

Philadelphia, PA

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Allegheny Endocrinology Associates

mi

from

Pittsburgh, PA

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

UT Soutwestern Medical Center at Dallas

mi

from

Dallas, TX

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

Status: Archived

Sentara Norfolk General Hospital

mi

from

Norfolk, VA

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals

Status: Archived

University of North Carolina Hospital at Chapel Hill

mi

from

Chapel Hill, NC

Asthma Exacerbation and Helium-3 MRI

Status: Archived

Umass Memorial Medical Center

mi

from

Worcester, MA

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

Status: Archived

Umass Memorial Medical Center

mi

from

Worcester, MA

Parents of Asthmatics Quit Smoking

Sustaining Cessation in Smokers With Kids With Asthma

Status: Archived

St. Anne's Hosptial

mi

from

Fall River, MA

Parents of Asthmatics Quit Smoking

Sustaining Cessation in Smokers With Kids With Asthma

Status: Archived

The Miriam Hospital Weight Control and Diabetes Research Center

mi

from

Providence, RI

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

Status: Archived

National Jewish Health

mi

from

Denver, CO

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

Status: Archived

Duke Asthma, Allergy and Airway Center

mi

from

Durham, NC

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11006 Boehringer Ingelheim Investigational Site

mi

from

Huntington Beach, CA

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11001 Boehringer Ingelheim Investigational Site

mi

from

Centennial, CO

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11012 Boehringer Ingelheim Investigational Site

mi

from

Wheat Ridge, CO

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11002 Boehringer Ingelheim Investigational Site

mi

from

Overland Park, KA

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11004 Boehringer Ingelheim Investigational Site

mi

from

North Dartmouth, MA

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11011 Boehringer Ingelheim Investigational Site

mi

from

St Louis, MO

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11009 Boehringer Ingelheim Investigational Site

mi

from

Skillman, NJ

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1222.29.11003 Boehringer Ingelheim Investigational Site

mi

from

Raleigh, NC

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

1199.14.1174 Boehringer Ingelheim Investigational Site

mi

from

Canton, OH

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

Boehringer Ingelheim Investigational Site

mi

from

Cincinnati, OH

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

Boehringer Ingelheim Investigational Site

mi

from

Spartanburg, SC

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the RespimatÂ® Inhaler in Patients With Moderate to Severe Asthma

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the RespimatÂ® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma

Status: Archived

Boehringer Ingelheim Investigational Site

mi

from

Richmond, VA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Clinical research Center of Alabama

mi

from

Birmingham, AL

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Medical Research of Arizona

mi

from

Scottsdale, AZ

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

California Allergy & Asthma Medical Group

mi

from

Palmdale, CA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Institute of HealthCare Assessment, Inc.

mi

from

San Diego, CA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Avail Clinical Research

mi

from

DeLand, FL

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Sarasota Clinical Research

mi

from

Sarasota, FL

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Atlanta Allergy & Asthma Clinic

mi

from

Woodstock, GA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Lapeer Regional Medical Center

mi

from

Lapeer, MI

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Allergy Partners of Western North Carolina

mi

from

Asheville, NC

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Peters Medical Research

mi

from

HIgh Point, NC

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Toledo Center for Clinical Research

mi

from

Sylvania, OH

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Allergy, Asthma and clinical Research Center

mi

from

Oklahoma City, OK

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Clinical Research Institute of Southern Oregon, PC

mi

from

Medford, OR

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Allergy & Asthma Research of New Jersey, Inc.

mi

from

Philadelphia, PA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Spartanburg Medical Research

mi

from

Spartanburg, SC

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

VA Adult & Pediatric Allergy & Asthma PC

mi

from

Richmond, VA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Bellingham Asthma, Allergy, & Immunology Clinic

mi

from

Bellingham, WA

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma

Status: Archived

Medical College of Wisconsin

mi

from

Milwaukee, WI